# AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Source: https://onco.cc/trials/nct06219941/  
OnCo record `nct06219941` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sonesitatug vedotin, FLOT, FOLFIRI in pancreatic ductal adenocarcinoma, run by AstraZeneca, now recruiting.

## Summary

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 is a phase 2 interventional study registered as NCT06219941 by AstraZeneca, with 226 participants planned, started 2023-12-13 and due to reach its primary completion in 2026-11-17. Interventions recorded: AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan. Conditions listed: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06219941
- Phase: 2
- Setting: A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)
- Sponsor: AstraZeneca
- Enrolled: 226

## Sources

- ClinicalTrials.gov NCT06219941: https://clinicaltrials.gov/study/NCT06219941

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/), [Sonesitatug vedotin](https://onco.cc/drugs/cmg901/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06219941.json